Time filter

Source Type

Patent
Nippon Zoki Pharmaceutical Co. | Date: 2017-01-25

An object of the present invention is to provide a preventive or therapeutic agent for inflammatory diseases or degenerative intervertebral disk diseases. A coumarin derivative or a pharmaceutically acceptable salt or hydrate thereof which is an active ingredient of the preventive or therapeutic agent of the present invention exhibits an excellent suppressive action in a pharmacological test where production of inflammation-related factor such as inflammatory cytokine or fibrosis-related factor as an index. Moreover, said compound also exhibits an excellent suppressive action to pulmonary fibrosis model animals and degenerative intervertebral disk disease model animals. Accordingly, the present invention is very useful as a preventive or therapeutic agent for inflammatory diseases and degenerative intervertebral disk diseases.


Patent
Nippon Zoki Pharmaceutical Co. | Date: 2017-01-04

An object of the present invention is to provide a pharmaceutical agent which is administered to a patient with chronic kidney disease in which the progress of worsening of renal function is rapid whereby the progress of the symptom is suppressed or improved. The present invention relates to a progress-suppressing or improving agent for chronic kidney disease containing 5-hydroxy-1-methylhydantoin as an active ingredient. The pharmaceutical agent of the present invention showed a significant effect in a patient with chronic kidney disease where progress of the renal function decrease is rapid. The present pharmaceutical agent is very useful as a highly safe pharmaceutical agent which suppresses or improves the progress of worsening of the renal function of a patient with rapidly progressive chronic kidney disease for which there has been no effective therapeutic agent being simply and easily ingestible.


Patent
Nippon Zoki Pharmaceutical Co. | Date: 2015-03-19

A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.


Patent
Nippon Zoki Pharmaceutical Co. and Nagoya Industrial Science Research Institute | Date: 2015-03-04

An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing at least one member selected from a trans-2-decenoic acid derivative represented by the formula (1) and a pharmaceutically acceptable salt thereof as an active ingredient:


Patent
Nippon Zoki Pharmaceutical Co. and Nagoya Industrial Science Research Institute | Date: 2015-03-04

The present invention relates to a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical agent containing the compound as an active ingredient. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt, which is the compound of the present invention, is specifically represented by the general formula (I):


Patent
National Center For Child Health And Development and Nippon Zoki Pharmaceutical Co. | Date: 2015-02-11

An object of the present invention is to provide DNA which regulates the expression of miR-140, a reporter vector which contains the DNA, cells and animals into which the reporter vector is introduced and a screening system for drugs which control the expression of miR-140 and is also to contribute in the development of new therapeutic agents for cartilage diseases such as osteoarthritis and intervertebral disk degeneration using the screening system. The DNA sequence according to the present invention is able to express any gene in a site where miR-140 is expressed and, in addition, it is also able to be utilized for screening a drug which regulates the expression of miR-140. Moreover, the drug that is selected by the screening system of the present invention is expected as a therapeutic agent for cartilage diseases accompanied by abnormality of cartilage.


Patent
Nippon Zoki Pharmaceutical Co. and Technoplan Inc. | Date: 2015-05-18

To provide a sludge treatment method and a sludge treatment system suppressing the fuel costs which can be utilized in the existing treatment facilities that drying and discharging after dehydrating a sludge as a useful improvement for the facility. This invention provides the solution means including a dehydration step of obtaining a dehydrated sludge, a liquefaction step of obtaining a slurry-like sludge, a branching step of branching a digested sludge, a vacuum deaeration step of deaerating a first digested sludge, a reprocessing step of ejecting a high-temperature steam and returning a concentrated digested sludge, a dehydration separation treatment step of separating a second digested sludge, a step of deaerating a digested sludge, a branching step of branching the mixed phase fluid, a step of returning a first mixed phase fluid, and a step of returning a second mixed phase fluid.


Patent
Nippon Zoki Pharmaceutical Co. | Date: 2015-07-29

The purpose of the present invention is to provide a novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient. The coumarin derivative of the present invention or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sGAG) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis.


Patent
Nippon Zoki Pharmaceutical Co. | Date: 2015-08-26

It is an object of the present invention to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus wherein the quality is more stabilized, and a preparation containing the extract, etc. The use of the amount of N-acetylneuraminic acid contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and a preparation containing the extract as an index makes possible to warrant the quality of each manufacturing lot of the extract and the preparation in more stable manner. The extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing the extract which are manufactured as above, and in which the quality thereof becomes more stable, are warranted to maintain efficacy and safety in more strict manner, and thus extremely useful.


Patent
Nippon Zoki Pharmaceutical Co. | Date: 2016-03-09

An object of the present invention is to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus where the quality of the extract is more stabilized and also to provide a preparation, etc. containing said extract as an active ingredient. When the amount of sulfated tyrosine contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and also contained in a preparation containing said extract as an active ingredient is used as an index, the quality of the extract and the preparation among the manufacturing lots can be warranted as a more stabilized one. In the extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing said extract where the quality thereof is more stabilized by such a method, the efficacy and the safety thereof are now guaranteed more strictly resulting in very high usefulness.

Loading Nippon Zoki Pharmaceutical Co. collaborators
Loading Nippon Zoki Pharmaceutical Co. collaborators